Meyer-Schwesinger Catherine, Dehde Silke, von Ruffer Claudia, Gatzemeier Stefan, Klug Philipp, Wenzel Ulrich O, Stahl Rolf A K, Thaiss Friedrich, Meyer Tobias N
Department of Internal Medicine, University Hospital Hamburg, Hamburg, Germany.
Am J Physiol Renal Physiol. 2009 May;296(5):F1088-99. doi: 10.1152/ajprenal.90746.2008. Epub 2009 Feb 18.
Rho kinase signaling regulates inflammatory cell migration and chemokine production. We therefore investigated the mechanisms of Rho-kinase-dependent inflammation in lipopolysaccharide (LPS)-induced renal failure. C57/BL6 mice received intraperitoneal LPS with or without daily treatment with specific Rho kinase inhibitors (Y-27632 or HA-1077; 5 mg/kg). Rho kinase inhibitors were applied in a preventive (12 or 1 h before LPS) or a therapeutic (6 h after LPS) scheme. Both protected renal function and decreased tubular injury in LPS-treated mice. Enhanced Rho kinase activity was inhibited by HA-1077 in capillary endothelial cells, inflammatory cells, and tubuli by analysis of Rho kinase substrate phosphorylation. Early neutrophil influx was reduced by HA-1077 without reduction of the proinflammatory cytokine TNFalpha. In contrast, HA-1077 decreased the influx of monocytes/macrophages coinciding with reduced expression of the NF-kappaB-regulated chemokines CCL5 and CCL2. We therefore examined NF-kappaB signal transduction and found that NF-kappaB p65 phosphorylation and nuclear translocation were reduced by Rho kinase inhibition. IkappaBalpha degradation was not altered during the first 6 h but was reduced by HA-1077 at later time points. NF-kappaB p50-deficient mice were similarly protected from renal injury by Rho kinase inhibition further supporting the prominent role for p65 in Rho kinase inhibition. Together, these data suggest that Rho kinase inhibition by preventive or therapeutic treatment effectively reduced endotoxic kidney injury in part by attenuation of NF-kappaB p65 activation.
Rho激酶信号传导调节炎症细胞迁移和趋化因子产生。因此,我们研究了脂多糖(LPS)诱导的肾衰竭中Rho激酶依赖性炎症的机制。C57/BL6小鼠腹腔注射LPS,同时给予或不给予特异性Rho激酶抑制剂(Y-27632或HA-1077;5mg/kg)每日治疗。Rho激酶抑制剂采用预防性(LPS前12或1小时)或治疗性(LPS后6小时)给药方案。二者均保护了LPS处理小鼠的肾功能并减轻了肾小管损伤。通过分析Rho激酶底物磷酸化发现,HA-1077抑制了毛细血管内皮细胞、炎症细胞和肾小管中增强的Rho激酶活性。HA-1077减少了早期中性粒细胞浸润,但未降低促炎细胞因子TNFα。相反,HA-1077减少了单核细胞/巨噬细胞的浸润,同时降低了NF-κB调节的趋化因子CCL5和CCL2的表达。因此,我们检测了NF-κB信号转导,发现Rho激酶抑制可降低NF-κB p65磷酸化和核转位。IκBα降解在最初6小时内未改变,但在后期时间点被HA-1077降低。Rho激酶抑制同样保护NF-κB p50缺陷小鼠免受肾损伤,进一步支持了p65在Rho激酶抑制中的重要作用。总之,这些数据表明,预防性或治疗性抑制Rho激酶可有效减轻内毒素性肾损伤,部分原因是减弱了NF-κB p65的激活。